ICCC
NASDAQImmuCell Corporation
ImmuCell Corporation (ICCC) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for ICCC, including 2 earnings updates and 2 SEC filings. The most recent was published Nov 12, 2026.
Financial highlights
Full financials- Revenue, TTM
- $30.68M
- Revenue growth
- +8.5%
- Net income, TTM
- $787.4K
- Net margin
- 2.6%
- Free cash flow, TTM
- $4.21M
- Cash
- $8.86M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks15+100%
2026-05-172026-11-08
Mix690d
- Earnings3(50%)
- SEC Filings3(50%)
Activity · 52 weeks6137 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by ImmuCell Corporation10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended September 30, 2026. Management’s Discussion: "Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part b
- SECSEC Form S-8 filed by ImmuCell CorporationS-8 - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026PORTLAND, Maine, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended September 30, 2026 after the market closes on Thursday, November 12, 2026. The Company is planning to host a conference call and webcast on November 13, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). The live webcast can be accessed at: https://
- SECSEC Form 8-K filed by ImmuCell Corporation8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales ResultsPORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026. "Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.9 million, a 29.2% increase compared to 2025," said Timothy Fiori, Chief Financial Officer of ImmuCell. "We are pleased with the sales results experienced during the third quarter of 2026, recognizi
- SECSEC Form 10-Q filed by ImmuCell Corporation10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026. Management’s Discussion: "Today we are reporting net income of $1.8 million for the second quarter of 2026," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "Revenue grew 11.5% to $7.2 million in the second quarter of 2026, which is a strong positive market signal in the face of high revenue in the second quarter of 2025 driven by distributor-restock
- PRImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026. The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). The live webcast can be accessed at: https://app.webina
- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales ResultsPORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026. "Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025," said Timothy Fiori, Chief Financial Officer of ImmuCell. "Our growth in the second quarter is particularly significant given the challenging comparison with the sec
- INSIDERPresident and CEO Te Boekhorst Paul Francis Olivier bought $75,960 worth of shares (8,000 units at $9.49), increasing direct ownership by 82% to 17,785 units (SEC Form 4)4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECImmuCell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECImmuCell Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECSEC Form 10-Q filed by ImmuCell Corporation10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended March 31, 2026. Management's Discussion: "Today we are reporting net income of $1.9 million for the first quarter of 2026, which is an increase of $0.5 million compared to the first quarter of 2025," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects
- SECAmendment: SEC Form 10-K/A filed by ImmuCell Corporation10-K/A - IMMUCELL CORP /DE/ (0000811641) (Filer)
- SECImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended March 31, 2026 after the market closes on Thursday, May 14, 2026. The Company is planning to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 22,
- SECSEC Form DEF 14A filed by ImmuCell CorporationDEF 14A - IMMUCELL CORP /DE/ (0000811641) (Filer)
- INSIDERSEC Form 3 filed by new insider Dimarco Anthony3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Guillemette Gilles3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Turner Kathy V4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
ICCC FAQ
10 questionsWhat does ImmuCell Corporation do?
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and...What is the latest news on ICCC?
In the last 30 days Quantisnow tracked 4 wire items for ICCC: 2 earnings updates and 2 SEC filings. The most recent was published on November 12, 2026.What is ICCC revenue?
ImmuCell Corporation (ICCC) reported $30.68M of revenue for the twelve months ended Jun 30, 2026. That is up 8.5% from the year before. Revenue for fiscal 2025 was $27.64M.Is ICCC profitable?
Yes. ImmuCell Corporation earned $787.4K in net income for the twelve months ended Jun 30, 2026, a net margin of 2.6%.How much cash and debt does ICCC have?
ImmuCell Corporation reported $8.86M in cash and cash equivalents and $8.30M of debt on its most recent balance sheet in SEC filings.Where does ICCC stock trade?
ImmuCell Corporation (ICCC) is listed on NASDAQ.What sector and industry is ICCC in?
ImmuCell Corporation operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did ImmuCell Corporation go public?
ImmuCell Corporation (ICCC) completed its IPO in 1987.What companies are similar to ICCC?
Notable peers in the same industry include LNTH (Lantheus Holdings Inc.), NTLA (Intellia Therapeutics Inc.), ACHV (Achieve Life Sciences Inc.), ORKA (Oruka Therapeutics Inc.), CLDX (Celldex Therapeutics Inc.). Compare ICCC side-by-side with any of them on Quantisnow.How can I track ICCC on Quantisnow?
Quantisnow aggregates ImmuCell Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICCC to receive live email and push alerts on every new disclosure.